Abstract
There is increasing evidence suggesting that the establishment of Pim-3 is involved in tumorigenesis. This study aimed to investigate the expression and clinicopathological significance of Pim-3 in colorectal cancer (CRC). Clinical pathology data were collected from 410 CRC patients who received radical resection and were pathologically confirmed at the Sun Yat-Sen University Cancer Center between October 2002 and December 2008. We compared the expression Pim-3 in the primary focus and liver metastasis and investigated the correlations with other clinical-pathological factors. Multivariate analysis showed that perioperative blood transfusion, local invasion, lymph node and liver metastasis, and Pim-3 expression were independent prognostic factors. The expression of Pim-3 in CRC was higher than that in normal tissues. Patients with positive expression had significant decreases in 5-year survival. Pim-3 expression showed a positive correlation with tumor cell differentiation, local infiltration, and lymph node and liver metastasis. In conclusion, Pim-3 might serve as a novel target and prognosis factor for colorectal cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, et al. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 2013;25:10–21.
Cuypers HT, Selten G, Quint W, Zijlstra M, Maandag ER, Boelens W, et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell. 1984;37:141–50.
Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer. 2011;11:23–34.
Narlik-Grassow M, Blanco-Aparicio C, Carnero A. The Pim family of serine/threonine kinases in cancer. Med Res Rev. 2014;34:136–59.
Mukaida N, Wang YY, Li YY. Roles of Pim-3, a novel survival kinase, in tumorigenesis. Cancer Sci. 2011;102:1437–42.
Peng YH, Li JJ, Xie FW, Chen JF, Yu YH, Ouyang XN, et al. Expression of Pim-1 in tumors, tumor stroma and tumor-adjacent mucosa co-determines the prognosis of colon cancer patients. PLoS One. 2013;8, e76693.
Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010;28:1254–61.
Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005;352:476–87.
Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011–9.
Lou L, Wang Y, Cui J, Yan X, Xue L, Li Y. Differential expression of Pim-3, c-Myc, and p-p27 proteins in adenocarcinomas of the gastric cardia and distal stomach. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014;35:5029–36.
Liang C, Yu XJ, Guo XZ, Sun MH, Wang Z, Song Y, et al. MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine. Oncotarget. 2015;6:14440–55.
Quan J, Zhou L, Qu J. Knockdown of Pim-3 suppresses the tumorigenicity of glioblastoma by regulating cell cycle and apoptosis. Cell Mol Biol. 2015;61:42–50.
Zhuang H, Zhao MY, Hei KW, Yang BC, Sun L, Du X, et al. Aberrant expression of Pim-3 promotes proliferation and migration of ovarian cancer cells. Asian Pac J Cancer Prev. 2015;16:3325–31.
Li YY, Mukaida N. Pathophysiological roles of Pim-3 kinase in pancreatic cancer development and progression. World J Gastroenterol. 2014;20:9392–404.
Liu LH, Lai QN, Chen JY, Zhang JX, Cheng B. Overexpression of Pim-3 and protective role in lipopolysaccharide-stimulated hepatic stellate cells. World J Gastroenterol. 2015;21:8858–67.
Ul-Haq Z, Gul S, Usmani S, Wadood A, Khan W. Binding site identification and role of permanent water molecule of Pim-3 kinase: a molecular dynamics study. J Mol Graph Model. 2015;62:276–82.
Cervantes-Gomez F, Lavergne B, Keating MJ, Wierda WG, Gandhi V. Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells. Leukemia lymphoma. 2015;1–9.
Keeton EK, McEachern K, Dillman KS, Palakurthi S, Cao Y, Grondine MR, et al. Azd1208, a potent and selective Pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014;123:905–13.
Zhang G, Liu Z, Cui G, Wang X, Yang Z. MicroRNA-486-5p targeting Pim-1 suppresses cell proliferation in breast cancer cells. Tumour Biol. 2014;35:11137–45.
Acknowledgments
This study was supported by grants from the Guangdong Academy of Medical Science and Technology Research Foundation (No. B2012137).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflicts of interest
None
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Zhongguo Zhou, Rongxin Zhang and Ruojing Wang contributed equally to this work.
Rights and permissions
About this article
Cite this article
Zhou, Z., Zhang, R., Wang, R. et al. Expression of Pim-3 in colorectal cancer and its relationship with prognosis. Tumor Biol. 37, 9151–9156 (2016). https://doi.org/10.1007/s13277-016-4806-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-016-4806-7